Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant

被引:91
作者
Shaw, B. E. [1 ,2 ]
Mufti, G. J. [3 ]
Mackinnon, S. [4 ]
Cavenagh, J. D. [5 ]
Pearce, R. M. [6 ]
Towlson, K. E. [6 ]
Apperley, J. F. [7 ]
Chakraverty, R. [4 ]
Craddock, C. F. [8 ]
Kazmi, M. A. [9 ]
Littlewood, T. J. [10 ]
Milligan, D. W. [11 ]
Pagliuca, A. [3 ]
Thomson, K. J. [4 ]
Marks, D. I. [12 ]
Russell, N. H. [13 ]
机构
[1] Royal Marsden Hosp, Inst Canc Res, Dept Haematol, BLB, Sutton SM2 5NG, Surrey, England
[2] Royal Free Hosp, Anthony Nolan Res Inst, London NW3 2QG, England
[3] Kings Coll Hosp London, Dept Haematol, London, England
[4] Royal Free & Univ Coll Med Sch, Dept Med, London WC1E 6BT, England
[5] Barts Hosp, Dept Haematol, London, England
[6] British Soc Blood & Marrow Transplantat, London, England
[7] Hammersmith Hosp, Dept Haematol, London, England
[8] Queen Elizabeth Hosp, Dept Haematol, Birmingham, W Midlands, England
[9] Guys Hosp, Dept Haematol, London SE1 9RT, England
[10] John Radcliffe Hosp, Dept Haematol, Oxford OX3 9DU, England
[11] Birmingham Heartlands Hosp, Dept Haematol, Birmingham B9 5ST, W Midlands, England
[12] Bristol Childrens Hosp, Dept Haematol, Bristol, Avon, England
[13] Univ Nottingham Hosp, Dept Haematol, Nottingham NG7 2UH, England
基金
英国医学研究理事会;
关键词
second allograft; reduced-intensity transplant; relapse; malignancy; TRM;
D O I
10.1038/bmt.2008.255
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Disease relapse following an allogeneic transplant remains a major cause of treatment failure, often with a poor outcome. Second allogeneic transplant procedures have been associated with high TRM, especially with myeloablative conditioning. We hypothesized that the use of reduced-intensity conditioning (RIC) would decrease the TRM. We performed a retrospective national multicentre analysis of 71 patients receiving a second allogeneic transplant using RIC after disease relapse following an initial allogeneic transplant. The majority of patients had leukaemia/myelodysplasia (MDS) (N=57), nine had lymphoproliferative disorders, two had myeloma and three had myeloproliferative diseases. A total of 25% of patients had unrelated donors. The median follow-up was 906 days from the second allograft. The predicted overall survival ( OS) and TRM at 2 years were 28 and 27%, respectively. TRM was significantly lower in those who relapsed late (> 11 months) following the first transplant ( 2 years: 17 vs 38% in early relapses; P=0.03). Two factors were significantly associated with a better survival: late relapse (P=0.014) and chronic GVHD following the second transplant (P=0.014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant.
引用
收藏
页码:783 / 789
页数:7
相关论文
共 34 条
[1]   Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience [J].
Arellano, Martha L. ;
Langston, Amelia ;
Winton, Elliott ;
Flowers, Christopher R. ;
Waller, Edinind K. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) :116-123
[2]   Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning [J].
Bethge, WA ;
Hegenbart, U ;
Stuart, MJ ;
Storer, BE ;
Maris, MB ;
Flowers, MED ;
Maloney, DG ;
Chauncey, T ;
Bruno, B ;
Agura, E ;
Forman, SJ ;
Blume, KG ;
Niederwieser, D ;
Storb, R ;
Sandmaier, BM .
BLOOD, 2004, 103 (03) :790-795
[3]   Second allogeneic bone marrow transplantation in acute leukemia: A multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) [J].
Bosi, A ;
Bacci, S ;
Miniero, R ;
Locatelli, F ;
Laszlo, D ;
Longo, G ;
Busca, A ;
VanLint, MT ;
DiBartolomo, P ;
Amici, A .
LEUKEMIA, 1997, 11 (03) :420-424
[4]   Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation [J].
Bosi, A ;
Laszlo, D ;
Labopin, M ;
Reffeirs, J ;
Michallet, M ;
Gluckman, E ;
Alessandrino, PE ;
Locatelli, F ;
Vernant, JP ;
Sierra, J ;
Jouet, JP ;
Frassoni, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3675-3684
[5]   Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies [J].
Branson, K ;
Chopra, R ;
Kottaridis, PD ;
McQuaker, G ;
Parker, A ;
Schey, S ;
Chakraverty, RK ;
Craddock, C ;
Milligan, DW ;
Pettengell, R ;
Marsh, JCW ;
Linch, DC ;
Goldstone, AH ;
Williams, CD ;
Mackinnon, S .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :4022-4031
[6]   Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study [J].
Choi, SJ ;
Lee, JH ;
Lee, JH ;
Kim, S ;
Lee, YS ;
Seol, M ;
Ryu, SG ;
Lee, JS ;
Kim, WK ;
Jang, S ;
Park, CJ ;
Chi, HS ;
Lee, KH .
BONE MARROW TRANSPLANTATION, 2005, 36 (02) :163-169
[7]   Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse [J].
Choi, SJ ;
Lee, JH ;
Lee, JH ;
Kim, S ;
Seol, M ;
Lee, YS ;
Lee, JS ;
Kim, WK ;
Chi, HS ;
Lee, KH .
LEUKEMIA, 2004, 18 (11) :1789-1797
[8]   Donor leukocyte infusions in acute lymphocytic leukemia [J].
Collins, RH ;
Goldstein, S ;
Giralt, S ;
Levine, J ;
Porter, D ;
Drobyski, W ;
Barrett, J ;
Johnson, M ;
Kirk, A ;
Horowitz, M ;
Parker, P .
BONE MARROW TRANSPLANTATION, 2000, 26 (05) :511-516
[9]   Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant [J].
Eapen, M ;
Giralt, SA ;
Horowitz, MM ;
Klein, JP ;
Wagner, JE ;
Zhang, MJ ;
Tallman, MS ;
Marks, DI ;
Camitta, BM ;
Champlin, RE ;
Ringdén, O ;
Bredeson, CN ;
Martino, R ;
Gale, RP ;
Cairo, MS ;
Litzow, MR ;
deLima, M .
BONE MARROW TRANSPLANTATION, 2004, 34 (08) :721-727
[10]   Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions [J].
Huff, CA ;
Fuchs, EJ ;
Smith, BD ;
Blackford, A ;
Garrett-Mayer, E ;
Brodsky, RA ;
Flinn, IW ;
Ambinder, RF ;
Borrello, IM ;
Matsui, WH ;
Vogelsang, GB ;
Griffin, CA ;
Luznik, L ;
Jones, RJ .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (04) :414-421